Final regression model highlighting the bivalirudin effect across PCI indications
| β | SE | Wald | df | p Value | OR | Lower CI | Upper CI | |
|---|---|---|---|---|---|---|---|---|
| STEMI | ||||||||
| Anticoagulant (heparin 0/bivalirudin 1) | 0.589 | 0.62 | 0.9 | 1 | 0.340 | 1.80 | 0.54 | 6.04 |
| NSTEMI | ||||||||
| Anticoagulant (heparin 0/bivalirudin 1) | −1.57 | 0.52 | 9.2 | 1 | 0.002 | 0.21 | 0.07 | 0.57 |
| Stable Angina | ||||||||
| Anticoagulant (heparin 0/bivalirudin 1) | −1.96 | 0.88 | 5.0 | 1 | 0.025 | 0.014 | 0.02 | 0.78 |
Adjusted for confounding variables from table 5.
NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction.